Alexander, John H, Lopes, Renato D, James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L, Goodman, Shaun, Verheugt, Freek W, Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E, Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H, Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A and Wallentin, Lars and APPRAISE-2 Investigators (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. New England Journal of Medicine, 365 (8). pp. 699-708. ISSN 0028-4793

Full text not available from this repository. (Request a copy)

Abstract

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.

Item Type:	Article
Uncontrolled Keywords:	acute coronary syndrome,aged,angina, unstable,aspirin,double-blind method,drug therapy, combination,factor xa,female,hemorrhage,humans,kaplan-meier estimate,male,middle aged,myocardial infarction,platelet aggregation inhibitors,proportional hazards models,pyrazoles,pyridones,stroke,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	06 Jan 2014 15:20
Last Modified:	30 Sep 2026 21:40
URI:	https://uea-test-2026.eprints-hosting.org/id/eprint/46236
DOI:	10.1056/NEJMoa1105819

Actions (login required)

View Item